Related Experiment Videos
Long-circulating vectors for the systemic delivery of genes
D B Fenske1, I MacLachlan, P R Cullis
1Department of Biochemistry and Molecular Biology, University of British Columbia, 2146 Health Sciences Mall, Vancouver, BC, Canada. fenske@interchange.ubc.ca
Current Opinion in Molecular Therapeutics
|May 8, 2001
Summary
Non-viral gene therapy vectors face rapid clearance. Liposomal systems, like stabilized plasmid-lipid particles (SPLPs), show promise for systemic disease treatment by prolonging circulation and targeting tumors.
Area of Science:
- Gene Therapy
- Nanomedicine
- Biotechnology
Background:
- Effective systemic gene therapy requires vectors with prolonged circulation times to reach disease sites.
- Conventional viral and non-viral vectors are rapidly cleared by organs like the liver, limiting their systemic efficacy.
- Targeting systemic diseases necessitates overcoming rapid clearance and preferential uptake by 'first-pass' organs.
Purpose of the Study:
- To review the literature on non-viral vectors for systemic gene therapy applications.
- To identify promising non-viral vector systems capable of improved circulation and targeted delivery.
- To highlight the potential of liposomal systems for treating systemic diseases.
Main Methods:
- Literature review of recent studies on non-viral gene delivery systems.
- Analysis of vector characteristics influencing circulation half-life and biodistribution.
- Evaluation of gene expression patterns following intravenous administration of non-viral vectors.
Main Results:
- Most viral and non-viral vectors are rapidly cleared from circulation, accumulating in the liver, lung, and spleen.
- Liposomal systems, particularly stabilized plasmid-lipid particles (SPLPs), demonstrate extended circulation half-lives (approx. 6 hours).
- SPLPs show preferential accumulation in distal tumors, with gene expression localized to the tumor site.
Conclusions:
- Liposomal systems represent a promising strategy for developing effective systemic gene therapy agents.
- Stabilized plasmid-lipid particles (SPLPs) offer a viable non-viral vector for targeted delivery and gene expression in systemic diseases.
- Further development of long-circulating non-viral vectors is crucial for advancing gene therapy for systemic conditions.